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844Objective: Bilateral internal thoracic artery (BITA) grafting has been shown to improve long-term survival after
coronary artery bypass grafting. However, there has been reluctance to use this technique in higher-risk patients.
Patients with reduced ejection fraction (EF) have been shown to present a higher operative risk and reduced
long-term survival. We studied the perioperative and long-term results of BITA versus single internal thoracic
artery grafting (SITA) in a large population of patients with reduced EF in whom BITA grafting was broadly
applied.
Methods: Between February 1972 and May 1994, 4537 consecutive patients in whom EF was recorded under-
went SITA (2340) or BITA (2197) grafting. Prospectively collected clinical data recorded EF categorically as
less than 0.30 (group I; n ¼ 233), 0.30 to 0.50 (group II; n ¼ 1256), or greater than 0.50 (group III;
n ¼ 3048). Multivariable analyses were performed to determine correlates of operative and late mortality.
Optimal matching using propensity scoring was used to create matched SITA and BITA cohorts: group I,
SITA and BITA, n ¼ 87 each; group II, SITA and BITA, n ¼ 448 each; group III, SITA and BITA, n ¼ 1137
each. Equality of survival distribution was tested by the log-rank algorithm.
Results: There was no difference in operative mortality between matched SITA and BITA groups (group I: SITA
vs BITA, 10.3% vs 6.9%, P ¼ .418; group II: 4.7% vs 4.5%, P ¼ .873; group III: 3.2% vs 2.0%, P ¼ .086).
SITA versus BITAwas not a predictor of operative mortality on logistic regression analysis. There was no dif-
ference in freedom from any postoperative complication, including sternal wound infection, between matched
SITA and BITA groups. Late survival was significantly enhanced with the use of BITA grafting in groups II and
III (10- and 20-year survival, SITA vs BITA, in group II: 57.7%  0.3% and 19%  2.5% vs 62.0%  2.3%
and 33.1%  3.4%, respectively, P ¼ .016; and in group III: 67.1%  1.4% and 35.8%  1.7% vs 74.6% 
1.3% and 38.1% 2.1%, respectively, P¼ .012). Likewise, choice of SITAversus BITAwas a significant pre-
dictor of late mortality on Cox regression in both groups II (P<.007) and III (P<.001).
Conclusions: Broadly applied BITA compared with SITA grafting in propensity-matched patients provides
enhanced long-term survival with no increase in operative mortality or morbidity for patients with normal
and reduced EF. The expanded use of BITA grafting should be seriously considered. (J Thorac Cardiovasc
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The Journal of Thoracic and Cardiovascular SurgTwenty-five years ago, we reported a 12-year experience
with 227 patients who underwent bilateral internal thoracic
artery (BITA) grafting with low operative risk and excellent
intermediate-term results.1 Several subsequent retrospec-
tive studies have documented an advantage for BITA over
single internal thoracic artery (SITA) grafting in reducing
late mortality and cardiac events.2-6
Patients with reduced ejection fraction (EF) undergoing
coronary artery bypass grafting (CABG) have an
increased operative mortality (OM)7-12 and reduced late
survival10,11,13-16 compared with patients with normal EF.
Because of the reluctance to use BITA grafting in patients
with increased risk, the impact of this surgical approach
on perioperative and long-term survival in this high-risk
group remains undefined. To determine the influence of
BITA grafting in patients with left ventricular dysfunction,
we report the clinical outcomes with a 30-year follow-upery c April 2012
Abbreviations and Acronyms
BITA ¼ bilateral internal thoracic artery
CABG ¼ coronary artery bypass grafting
EF ¼ ejection fraction
ITA ¼ internal thoracic artery
LAD ¼ left anterior descending
LITA ¼ left internal thoracic artery
OM ¼ operative mortality
RITA ¼ right internal thoracic artery
SITA ¼ single internal thoracic artery
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Dfrom a consecutive cohort of patients in whom one third had
impaired systolic function and approximately one half re-
ceived BITA grafting.MATERIALS AND METHODS
This report involves 4537 consecutive patients who underwent CABG
between February 1972 andMay 1994, 2340 of whom received SITA graft-
ing and 2197 received BITA grafting. Waiver of informed consent was
granted by the institutional review board. The study population consisted
of 146 patients receiving SITA and 87 patients receiving BITA with an
EF less than 0.30 (group I); 656 patients receiving SITA and 600 patients
receiving BITAwith an EF between 0.30 and 0.50 (group II); and 1538 pa-
tients receiving SITA and 1510 patients receiving BITAwith an EF greater
than 0.50 (group III). Appendix E1 shows a listing of clinical variables as-
sociated with unmatched patients. Excluded from this study were patients
with concomitant cardiovascular procedures and those in whom only 1 dis-
tal graft was performed. The series includes all elective, urgent, emergency,
and salvage cases.
To adjust for differences in patient risk factors, patients receiving SITA
and BITA in groups I, II, and III were matched by propensity score as de-
scribed in the ‘‘Statistical Analysis’’ section. Groups I, II, and III matched
patients constitute the clinical material for this comparative analysis. The
coronary and perioperative risk factors for propensity-matched patients
are summarized in Table 1. Although patients receiving SITA and BITA
had different risk profiles before matching, there were no significant differ-
ences in any of the risk factors in propensity-matched groups I, II, or III.
Patient preoperative anginal symptoms were defined by the Canadian
Cardiovascular Society. Patients with unstable angina included patients
with Canadian Cardiovascular Society class III or IV. In group I SITA, there
were 4 patients (4.6%) in class I, 1 patient (1.1%) in class II, 27 patients
(31.0%) in class III, and 55 patients (63.2%) in class IV. In group I
BITA, there were 7 patients (8.0%) in class I, 3 patients (3.4%) in class
II, 31 patients (35.6%) in class III, and 46 patients (52.9%) in class IV.
The distribution of class III or IV symptoms was comparable for patients
receiving SITA and BITA (94.2% vs 88.5%; P ¼ .280).
In group II SITA, there were 9 patients (2.0%) in class I, 18 patients
(4.0%) in class II, 191 patients (42.6%) in class III, and 230 patients
(51.3%) in class IV. In group II BITA, there were 16 patients (3.6%) in
class I, 23 patients (5.1%) in class II, 199 patients (46.9%) in class III,
and 199 patients (44.4%) in class IV. There was no significant difference
in the proportion of group II patients receiving SITA (93.9%) and BITA
(91.3%) who had class III or IV symptoms (P ¼ .127).
In group III SITA, there were 29 patients (2.6%) in class I, 62 patients
(5.5%) in class II, 579 patients (50.9%) in class III, and 467 patients
(41.1%) in class IV. In group III BITA, there were 38 patients (3.3%) in
class I, 69 patients (6.1%) in class II, 542 patients (47.7%) in class III,
and 488 patients (42.9%) in class IV. The distribution of class III or IVThe Journal of Thoracic and Casymptoms is similar for SITA and BITA in group III (92.0% vs 90.6%;
P ¼ .234).
Operative Data
The operation was performed in group I SITA electively in 27 cases
(31.0%), urgently in 47 cases (54.0%), on an emergency basis in 10 cases
(11.5%), and on a salvage basis in 3 cases (3.4%). In group I BITA, the op-
eration was performed electively in 30 cases (34.5%), urgently in 53 cases
(60.9%), on an emergency basis in 3 cases (3.4%), and on a salvage basis in
1 case (1.1%). A comparison of elective versus non-elective urgency re-
vealed no significant difference (P ¼ .630). Operations in 10 SITA
(11.5%) and 9 BITA (10.3%) cases were repeat operations (P ¼ .808).
In group II SITA, the operation was performed electively in 190 cases
(42.4%), urgently in 217 cases (48.4%), on an emergency basis in 36 cases
(8.0%), and on a salvage basis in 5 cases (1.1%). In group II BITA, the op-
eration was performed electively in 201 cases (44.9%), urgently in 229
cases (51.1%), on an emergency basis in 18 cases (4.0%), and on a salvage
basis in 0 cases (0.0%). The distribution of non-elective cases was similar
for the 2 cohorts (57.6% vs 55.1%; P ¼ .459).
In group III SITA, the operation was performed electively in 561 cases
(49.3%), urgently in 477 cases (42.0%), on an emergency basis in 94 cases
(8.3%), and on a salvage basis in 5 cases (0.4%). In group III BITA, the
operation was performed electively in 565 cases (49.7%), urgently in
533 cases (46.9%), on an emergency basis in 38 cases (3.3%), and on a sal-
vage basis in 1 case (0.1%). The distribution of nonelective cases was sim-
ilar for the 2 cohorts (50.7% vs 50.3%; P ¼ .867). Operations in 77
patients receiving SITA (6.8%) and 82 patients receiving BITA (7.2%)
were repeats (P ¼ .681).
Details of the operative technique used in the present series, including
internal thoracic artery (ITA) mobilization, orientation, and reconstruc-
tion in BITA grafting, have been published.1 The ITA is dissected from
the chest wall in a skeletonized fashion free from surrounding muscle
and fascia. The vein is initially dissected but subsequently removed to al-
low maximal length and versatility. All side branches are cauterized care-
fully or clipped as necessary. Since 1989, combined antegrade and
retrograde infusion methods of cardioplegia have been implemented to
enhance myocardial protection during the operation. Cardiopulmonary
bypass was used in all operations. The operative data for propensity-
matched patients, by group, are shown in Appendix E2. Operative
variables were mostly comparable between matched groups with the ex-
ception of the mean distal grafts (P ¼ .031) and aortic crossclamp time
(P ¼ .009) in group I. In groups II and III, the aortic crossclamp time
was, as expected, significantly greater for those receiving BITA than
for those receiving SITA (P<.001).
Data Collection and Management
Perioperative data were obtained by prospective review of the patient’s
hospital record, catheterization reports, cineangiograms, and echocardiog-
raphy. Follow-up information was obtained through comprehensive ques-
tionnaires and by telephone interview with surviving patients, family
members, or the patient’s personal physician. A Patient Registration
Form and a Patient Follow-Up Form were completed for each patient in
the study. Appendix E3 shows the definitions of terms.
Statistical Analysis
Demographic and clinical data are presented as frequency distributions
and simple percentages. Values of continuous variables are expressed as
mean  standard deviation. Univariate analysis of selected preoperative
and postoperative discrete variables was accomplished by chi-square, con-
tinuity-adjusted chi-square analysis, or 2-tailed Fisher exact test with the
appropriate degrees of freedom to test for the equality of proportions in
the case of categoric variables. Two-sample t tests (2-tailed) were used
to test for the equality of means of continuous variables.rdiovascular Surgery c Volume 143, Number 4 845
TABLE 1. Comparison of preoperative variables and risk factors in propensity-matched ejection fraction groups
Variable
Group I
matched patients
EF<0.30
Group II
matched patients
EF 0.30–0.50
Group III
matched patients
EF>0.50
SITA BITA P value SITA BITA P value SITA BITA P value
No. of patients 87 (100.0) 87 (100.0) 448 (100.0) 448 (100.0) 1137 (100.0) 1137 (100.0)
Gender .660 .282 .100
Male 74 (85.4) 76 (87.4) 382 (85.3) 393 (87.7) 859 (75.5) 892 (78.5)
Female 13 (14.9) 11 (12.6) 66 (14.7) 55 (12.3) 278 (24.5) 245 (21.5)
Age at operation
Mean  SD 64.4  10.5 63.2  9.4 .426 64.0  7.4 64.0  8.8 .944 63.6  8.2 63.7  9.4 .803
Coronary risk factors
Family history of CAD 42 (48.3) 45 (51.7) .649 237 (52.9) 241 (53.8) .789 625 (55.0) 629 (55.3) .866
Hypertension 15 (17.2) 16 (18.4) .843 153 (34.2) 150 (33.5) .832 409 (36.0) 424 (37.3) .514
Dyslipidemia 8 (9.2) 8 (9.2) 1.000 74 (16.5) 75 (16.7) .929 161 (14.2) 152 (13.4) .584
Smoking history 61 (70.1) 62 (71.3) .868 286 (63.8) 286 (63.8) 1.000 713 (62.7) 712 (62.6) .965
Diabetes mellitus 29 (33.3) 23 (26.4) .320 145 (32.4) 129 (28.8) .246 292 (25.7) 275 (24.2) .410
Preoperative risk factors
Renal dysfunction 5 (5.7) 5 (5.7) 1.000 24 (5.4) 19 (4.2) .435 43 (3.8) 35 (3.1) .357
Cerebrovascular disease 5 (5.7) 7 (8.0) .550 24 (5.4) 16 (3.6) .196 47 (4.1) 47 (4.1) 1.000
Peripheral artery disease 7 (8.0) 8 (9.2) .787 28 (6.3) 23 (5.1) .471 43 (3.8) 39 (3.4) .653
Prior myocardial infarction 67 (77.0) 69 (79.3) .714 353 (78.8) 347 (77.5) .628 565 (49.7) 560 (49.3) .834
History of CHF 29 (33.3) 24 (27.6) .410 89 (19.9) 67 (15.0) .053 86 (7.6) 80 (7.0) .629
Unstable angina 60 (69.0) 59 (67.8) .870 289 (64.5) 280 (62.5) .532 745 (65.5) 750 (66.0) .825
Coronary angiography
3-vessel disease 77 (88.5) 80 (92.0) .444 385 (85.9) 385 (85.9) 1.000 915 (80.5) 917 (80.7) .916
EF,Ejection fraction; SITA, single internal thoracic artery;BITA, bilateral internal thoracic artery;CAD, coronary artery disease;CHF, chronic heart failure; SD, standard deviation.
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DA propensity score was generated using a logistic regression model
based on 15 covariates as independent variables in each of the study groups.
Appendix E4 shows a listing of covariates used to generate a propensity
score. The treatment type (SITA vs BITA) was used as a binary dependent
variable. The resulting propensity score indicated that a patient underwent
BITA rather than SITACABG. Patients receiving BITAwere then matched
to patients receiving SITA in a 1:1 ratio using an optimal matching algo-
rithm. This approach minimized the overall distance between observations
and was conducted using Mahalanobis distance within propensity score
calipers (no matches outside the calipers).
To determine the predictors of hospital mortality, a hierarchic logistic
regression model was developed using preoperative and intraoperative var-
iables (Appendix E5 shows the list of variables used to generate themodel).
To identify risk factors associated with late mortality, a univariate analysis
of preoperative, intraoperative, and postoperative variables was performed.
Variables achieving statistical significance (P<.050) were then used to cre-
ate a Cox proportional hazards regression model to discern the influence of
multiple clinical variables on late survival. Covariates with borderline sig-
nificance in the univariate analysis and clinical relevance were also in-
cluded in the model. Regression coefficients and odds ratios with 95%
confidence intervals were calculated to determine the relative influence
of each covariate on the survivor function. Coefficients were computed
by the method of maximum likelihood (Appendix E6 shows the list of vari-
ables used in the Cox regression).
Actuarial survival estimates (including operative deaths) were calcu-
lated according to the Kaplan–Meier method using time zero as the
date of operation and late death as the end point (with variability ex-
pressed as the standard error of the mean). The equality of survival dis-
tribution was tested with the log-rank algorithm. All P values reported
are 2-sided and not adjusted for multiple testing. All analyses were per-
formed using Number Cruncher Statistical Systems software (NCSS,
Kaysville, Utah).846 The Journal of Thoracic and Cardiovascular SurgRESULTS
A series of postoperative complications are documented
from the dataset and reported in Table 2. The rate of no
complications for SITA versus BITA recipients in group I
was similar (72.4% vs 82.8%; P ¼ .102). In group II,
the rate of no complications for SITA versus BITA was
also similar (82.6% vs 81.5%; P ¼ .664). A comparison
of group I BITA recipients with group III BITA recipients
generated no significant difference (82.8% vs 86.9%;
P ¼ .275). An additional comparison of BITA recipients
in groups II and III revealed that a greater proportion of
group III BITA recipients experienced no in-hospital com-
plications (81.5% vs 86.9%; P ¼ .006). Incidence of no
complications in SITA versus BITA recipients in group
III approached statistical significance (84.1% vs 86.9%;
P ¼ .057). For the entire series, the incidence of no com-
plications was highest in group III BITA recipients
(86.9%).
On review of the individual morbidities across the 3
groups, respiratory insufficiency necessitating prolonged
mechanical ventilation was the most common complication
for patients in groups I and II. In group III, myocardial in-
farction appeared with the greatest frequency in both
SITA and BITA recipients.
The hospital mortality rate for all SITA recipients in the
series was 4.6% (107/2340) and 2.6% (57/2197) for all
BITA recipients (P < .001). The overall in-hospitalery c April 2012
TABLE 2. Comparison of postoperative complications in matched ejection fraction groups
Complication*
Group I
matched patients
EF<0.30
Group II
matched patients
EF 0.30–0.50
Group III
matched patients
EF>0.50
SITA BITA P value SITA BITA P value SITA BITA P value
No. of patients 87 (100.0) 87 (100.0) 448 (100.0) 448 (100.0) 1137 (100.0) 1137 (100.0)
No complications 63 (72.4) 72 (82.8) .102 370 (82.6) 365 (81.5) .664 956 (84.1) 988 (86.9) .057
Reoperation for bleeding 7 (8.0) 0 (0.0) .007 8 (1.8) 6 (1.3) .590 37 (3.3) 27 (2.4) .205
Low cardiac output 8 (9.2) 4 (4.6) .231 12 (2.7) 14 (3.1) .691 24 (2.1) 22 (1.9) .766
Cardiac arrest 7 (8.0) 3 (3.4) .193 13 (2.9) 20 (4.5) .214 33 (2.9) 31 (2.7) .800
Renal dysfunction 3 (3.4) 3 (3.4) 1.000 17 (3.8) 17 (3.8) 1.000 32 (2.8) 23 (2.0) .219
Myocardial infarction 5 (5.7) 1 (1.1) .097 25 (5.6) 18 (4.0) .274 74 (6.5) 59 (5.2) .180
Stroke 2 (2.3) 1 (1.1) .560 10 (2.2) 13 (2.9) .526 15 (1.3) 8 (0.7) .142
Respiratory insufficiency 11 (12.6) 9 (10.3) .635 26 (5.8) 35 (7.8) .233 43 (3.8) 51 (4.5) .400
Gastrointestinal 1 (1.1) 1 (1.1) 1.000 9 (2.0) 7 (1.6) .614 22 (1.9) 29 (2.6) .322
Sternal wound infection 2 (2.3) 2 (2.3) 1.000 5 (1.1) 7 (1.6) .561 13 (1.1) 17 (1.5) .462
EF, Ejection fraction; SITA, single internal thoracic artery; BITA, bilateral thoracic artery. *Numbers in parentheses are percentages.
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mortality increased with decreasing EF. Table 3 shows the
hospital mortality rates for unmatched and matched patient
groups and by procedure. Although statistical differences in
hospital mortality were noted in unmatched groups II and
III, there was no difference in any of the matched groups.
To identify independent correlates of hospital mortality,
17 preoperative and intraoperative variables were entered
into a forward stepwise logistic regression model for un-
matched patients (Appendix E7). In group I, age at opera-
tion (P ¼ .013) and use of the intra-aortic balloon pump
inserted preoperatively (P ¼ .005) were correlated with
in-hospital mortality. In group II, age at operation
(P ¼ .002), congestive heart failure (P ¼ .014), intra-
aortic balloon pump inserted preoperatively (P < .001),
and aortic crossclamp time (P ¼ .012) were associated
with in-hospital mortality. In group III, age at operation
(P< .001), intra-aortic balloon pump inserted preopera-
tively (P< .001), and aortic crossclamp time (P< .001)
were identified as predictors of hospital mortality. Of
note, use of BITA grafting was not predictive of hospital
mortality in any group.
Initial clinical follow-up data were collected for 96.4%
patients (4373/4537) discharged from the hospital: 98.2%
(2299/2340) SITA and 96.6% (2125/2197) BITA. The aver-
age duration of follow-up for unmatched hospital survivors
in group I was 7.0 years (range, 6 weeks to 21.5 years) in
SITA recipients and 7.9 years (range, 6 weeks to 30.5 years)
in BITA recipients. The cumulative follow-up was 1023.8
patient-years for the SITA group and 691.4 patient-years
for the BITA group. For group II, the average duration of
follow-up for unmatched hospital survivors was 9.4 years
(range, 6 weeks to 31.6 years) in SITA recipients and 11.4
years (range, 6 weeks to 31.7 years) in BITA recipients.
The cumulative follow-up was 6149.4 patient-years for
the SITA group and 6868.5 patient-years for the BITAThe Journal of Thoracic and Cagroup. The average duration of follow-up for unmatched
hospital survivors in group III was 11.5 years (range, 6
weeks to 30.9 years) in SITA recipients and 13.0 years
(range, 6 weeks to 32.1 years) in BITA recipients. The cu-
mulative follow-up was 17,758.8 patient-years for the
SITA group and 19,606.0 patient-years for the BITA group.
To identify independent predictors of late death, a Cox
proportional hazards regression model was created using
30 preoperative, intraoperative, and postoperative variables
to measure the effects of various prognostic factors on time
to response (operation to late death). Cox regression analy-
sis demonstrated the independence of a series of covariates
associated with late mortality for each of the unmatched
groups (Table 4). Of note, SITAversus BITA use was an in-
dependent predictor of late mortality in both groups II and
III, but not in group I.
The actuarial survival data for matched SITA and BITA
recipients by groups are shown in Figure 1. Appendix E8
shows the actuarial survival curves of unmatched patients.
Survivals were ( the standard error of the mean) 48.3%
 4.2% at 7 years and 20.7%  3.6% at 14 years in un-
matched group I SITA recipients and 51.7%  5.4% at 7
years and 26.7%  4.9% at 14 years in BITA recipients
(P ¼ .289). The median survival for SITA was 6.4 years
and 7.0 years for BITA. Survivals were 57.0%  5.3% at
7 years and 26.6%  5.1% at 14 years in matched group
I SITA recipients and 51.7%  5.4% at 7 years and
26.7%  4.9% at 14 years in BITA recipients
(P ¼ .934). The median survival was 8.5 years for SITA re-
cipients and 7.0 for BITA recipients.
Survivals were 49.4%  2.0% at 10 years and 15.0% 
2.0% at 20 years in unmatched group II SITA recipients and
66.2%  2.0% at 10 years and 36.8%  2.8% at 20 years
for BITA recipients (P< .001). The median survival for
SITA recipients was 9.9 years and 14.6 years for BITA re-
cipients. Survivals were 57.7%  2.3% at 10 years andrdiovascular Surgery c Volume 143, Number 4 847
TABLE 3. Comparison of hospital mortality by patient group
Group
SITA BITA
P valueN (%) N (%)
Group I, EF<0.30
Unmatched patients 17/146 (11.6) 6/87 (6.9) .240
Matched patients 9/87 (10.3) 6/87 (6.9) .418
Group II, EF 0.30–0.50
Unmatched patients 37/656 (5.6) 20/600 (3.3) .050
Matched patients 21/448 (4.7) 20/448 (4.5) .873
Group III, EF>0.50
Unmatched patients 53/1538 (3.4) 31/1510 (2.1) .019
Matched patients 36/1,137 (3.2) 23/1,137 (2.0) .086
SITA, Single internal thoracic artery; BITA, bilateral internal thoracic artery;
EF, ejection fraction.
TABLE 4. Multivariate analysis of demographic and preoperative clinic
unmatched ejection fraction groups
Group/predictor b Estimate
Group I, EF<0.30
Preoperative
Age at operation 0.038
Pulmonary insufficiency 0.775
Surgical urgency 0.417
Group II, EF 0.30–0.50
Preoperative
Age at operation 0.060
Congestive heart failure 0.298
Cerebrovascular disease 0.569
Diabetes 0.342
Peripheral arterial disease 0.443
Renal dysfunction (creatinine  2.0 mg/dL) 0.514
Smoking history 0.211
Intraoperative
SITA used 0.214
Postoperative
Stroke 0.606
Renal dysfunction (creatinine  2.0 mg/dL) 0.602
Group III, EF>0.50
Preoperative
Age at operation 0.072
Congestive heart failure 0.452
Cerebrovascular disease 0.387
Diabetes 0.507
Family history of coronary artery disease 0.110
Left main disease (>0.5) 0.202
Peripheral arterial disease 0.305
Prior myocardial infarction 0.229
Renal dysfunction (creatinine  2.0 mg/dL) 0.366
Smoking history 0.223
Intraoperative
SITA used 0.211
Crossclamp time 0.002
Postoperative
Cardiac arrest 0.649
Pulmonary insufficiency 0.363
Renal dysfunction (creatinine  2.0 mg/dL) 0.856
SE, Standard error; HR, hazard ratio; CI, confidence interval; EF, ejection fraction; SITA,
Acquired Cardiovascular Disease Galbut et al
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ients and 62.0% 2.3% at 10 years and 33.1% 3.4% at
20 years in BITA recipients (P¼ .016). The median survival
for SITA recipients was 11.6 years and 13.6 years for BITA
recipients.
Survivals were 45.7%  1.3% at 14 years and 11.1% 
3.3% at 28 years in unmatched group III SITA recipients
and 62.1%  1.3% at 14 years and 24.4%  3.1% at 28
years in BITA recipients (P<.001). The median survival
for SITA recipients was 12.8 years and 17.2 years for
BITA recipients. survivals were 54.4%  1.5% at 14 years
and 14.4%  4.2% at 28 years in matched group III SITA
recipients and 59.4%  1.5% at 14 years and 19.5%al variables influencing late mortality by Cox regression analysis in
SE HR (95% CI) P value*
0.0085 1.0 (1.0–1.0) <.001
0.2291 2.2 (1.4–3.4) .002
0.1762 1.5 (1.1–2.1) .015
0.0045 1.1 (1.1–1.1) <.001
0.0938 1.3 (1.1–1.6) .002
0.1613 1.8 (1.3–2.4) .001
0.0828 1.4 (1.2–1.7) <.001
0.1436 1.6 (1.2–2.1) .004
0.1559 1.7 (1.2–2.3) .002
0.0778 1.3 (1.1–1.4) .006
–
0.0787 0.8 (0.7–0.9) .007
0.2354 1.8 (1.2–2.9) .018
0.2055 1.8 (1.2–2.7) .007
0.0032 1.1 (1.1–1.1) <.001
0.0859 1.6 (1.3–1.9) <.001
0.1112 1.5 (1.2–1.8) .001
0.0569 1.7 (1.5–1.9) <.001
0.0510 0.9 (0.8–1.0) .031
0.0609 1.2 (1.1–1.4) .001
0.1124 1.4 (1.1–1.7) .009
0.0505 1.3 (1.1–1.4) <.001
0.1277 1.4 (1.1–1.9) <.001
0.0524 1.2 (1.1–1.4) <.001
0.0532 0.8 (0.7–0.9) <.001
0.0011 1.0 (1.0–1.0) .047
0.1787 1.9 (1.3–2.7) .001
0.1183 1.4 (1.1–1.8) .004
0.1516 2.4 (1.7–3.2) .007
single internal thoracic artery. *Only significant variables (P<.050) are listed.
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FIGURE 1. A, Matched group I SITA and BITA recipients (EF < 0.30). B, Matched group II SITA and BITA recipients (EF 0.30–0.50).
C, Matched group III SITA and BITA recipients (EF > 0.50). SITA, Single internal thoracic artery; BITA, bilateral internal thoracic artery;
EF, ejection fraction.
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D 3.4% at 28 years in BITA recipients (P¼ .012). The me-
dian survival for SITA recipients was 15.4 years and 16.0
years for BITA recipients. The equality of survival distribu-
tion demonstrated significant differences between un-
matched and matched group II and group III SITA versus
BITA recipients.
To further assess the impact of date of surgery on sur-
vival, the distribution of date of surgery was compared in
each of the 3 groups of matched patients. It was determined
that there was no significant difference in the distribution of
date of surgery in groups I and II. Therefore, inclusion of the
date of surgery in the matching algorithm would not have
changed the results. However, in group III, using chi-
square analysis, there was a statistically significant differ-
ence between the SITA and BITA groups in the distribution
of surgery date, with more of the BITA recipients undergo-
ing operation in the more recent years (P¼ .001) Therefore,
we redid the propensity matching for this group including
the data of surgery in the model to achieve groups that
were well matched with regard to the date of surgery and
all of the other variables outlined in the model. This gener-
ated a propensity score that was then used in the optimal
matching algorithm to create comparable groups. To assess
survival, a Kaplan–Meier curve was created for each of the
groups (SITA vs BITA), and a significant difference favor-
ing the BITA group was achieved using the log-rank test
(P ¼ .029)
DISCUSSION
During the past 20 years, OM in patients undergoing
CABG with left ventricular dysfunction has continued to
decrease but remains modestly greater than in those with
normal systolic function.7-12 Some studies have reported
intermediate-term follow-up with 5- and 7-year late sur-
vival ranging from 72% to 63%.11,12,14-16 A recent study
of 302 patients with left ventricular dysfunction reported
an OM of 5.3% and a 10-year survival of 63%  4%.13
SITA grafting was prevalent in these studies, but the impact
of BITA grafting has rarely been described.
Our study is unique in the broad application of BITA
grafting (approaching 48% of the study population), the
matching of patient cohorts receiving SITA or BITA graft-
ing in the 3 study groups, and the 30-year follow-up period.
The main findings of the present study included a modestly
greater OM in patients with left ventricular dysfunction
compared with those with normal systolic function, which
is consistent with the literature. Within matched groups of
patients receiving SITA or BITA grafting, there was no sig-
nificant difference in OM or complications. Late survival
was significantly enhanced with BITA grafting in matched
patients in group III (P ¼ .012) and group II (P ¼ .016).
BITA grafting exerted no influence in group I, possibly be-
cause of the small sample size or increased severity of left
ventricular dysfunction.850 The Journal of Thoracic and Cardiovascular SurgIn group II, the 10-year survival of patients receiving
BITA grafting was 62%  2% compared with 58% 
3% in those receiving SITA grafting. At 20 years in group
II, patients receiving BITA grafting had a late survival of
33% 3.4% compared with those receiving SITA grafting
of 19.1% 2.5%. This increased divergence is significant.
It is noteworthy that BITA grafting in group II at 20 years of
follow-up yields an outcome that is similar to the 20-year
late survival of group III patients receiving SITA grafting
(35.8%  1.7%).
It seems that a patient with reduced EF receiving BITA
compared with SITA grafting demonstrates a survival ad-
vantage that increases over time. This suggests that the
real benefit of BITA grafting is determined by a patient’s
age and ‘‘survival probability,’’ which may correlate with
certain comorbidities. Others have noted that diabetes,
chronic renal dysfunction, and ventricular arrhythmias are
predictors of late mortality in patients with left ventricular
dysfunction.13,17-19 This is consistent with our findings.
Recent data have demonstrated the efficacy of
implantable cardiodefibrillators in reducing late mortality
in patients with left ventricular dysfunction.20 Although
previous studies have failed to demonstrate any single co-
morbidity that removes the long-term survival benefit of
BITA grafting,6 our findings strongly suggest that patients
with a life expectancy of 1 to 2 decades should receive
BITA grafting.
In view of the clinical advantages of BITA grafting dem-
onstrated in the literature, its infrequent use in clinical prac-
tice is remarkable. The Society of Thoracic Surgeons
National Adult Cardiac Surgery Database reports that
only 4% of CABG procedures involve the use of BITA
grafting.21 Several concerns influence surgical decision
making. The adequacy of multiple ITA grafts to maintain
necessary hemodynamic parameters in the immediate post-
operative period has been questioned.22 The current study
refutes this concern because there was no difference in
OM or postoperative infarction between matched patients
receiving BITA or SITA in all 3 study groups. There are re-
ports of an increased incidence of sternal wound infection,
particularly in diabetic patients receiving BITA graft-
ing.23,24 Increased mediastinal bleeding and pulmonary
morbidity have also been reported with BITA grafting.25
In our study, there was no difference in sternal wound infec-
tion among matched patients (including diabetic patients)
receiving BITA or SITA grafting. This discrepancy may
be explained by our technique of skeletonizing the ITA,
which preserves the lymphatic vessels and more of the
blood supply to the sternum, compared with the more com-
monly used technique of ITA harvesting with a wide pedi-
cle.26 Although there was no difference in pulmonary
complications in matched patients receiving BITA or
SITA grafting in our study, contemporary criteria, which
measure the number of postoperative hours of mechanicalery c April 2012
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geons to perform shorter operations with SITA grafting.
Given the current focus on perioperative rather than long-
term outcomes, in a setting of increasingly complex patient
comorbidities, surgeons may be more likely to perform sim-
pler operations whenever possible. The left ITA bypass to
the left anterior descending artery, the most strategic graft
in promoting longevity in the majority of patients, can be
accomplished easily. In contrast, right ITA grafting can be
technically challenging. The usual practice of a wide pedi-
cle at ITA harvesting minimizes the length available to per-
form a tension-free anastomosis. Greater attention to the
orientation of the right ITA graft relative to the pericardium,
superior vena cava, aorta, and pulmonary artery and the cor-
onary artery target is needed to prevent twisting or compres-
sion of the conduit. Despite a recent report from our registry
demonstrating no difference in clinical outcome in matched
groups of patients receiving in situ right ITA to the left cor-
onary system (obtuse marginal branch, diagonal, or left an-
terior descending arteries) or the right coronary system,27
many surgeons remain uncertain as to the appropriate coro-
nary artery target vessel for right ITA grafting. Successful
right ITA grafting for most surgeons requires the experience
of a learning curve and more frequent than just occasional
use in CABG procedures.
Limitations
This study has the inherent limitations of being retrospec-
tive and nonrandomized. It is impossible to define the sub-
tlety of clinical judgment in determining which patients
received BITA or SITA grafting. Nevertheless, optimal
matching with propensity scoring is a helpful tool in validat-
ing the conclusions of this study. The guidelines in current
practice, which include postoperative patients being dis-
charged with a medical regimen of beta-blockers, angioten-
sin-converting enzyme inhibitors, platelet antagonists, and
lipid-lowering agents, and greater emphasis on lifestyle
modifications and risk factors may improve the long-term
outcome of patients undergoing CABG, thereby potentially
ameliorating the benefits observed. Moreover, although
BITA grafting was widely applied in this patient cohort,
there remains the possibility that a similar approach with
current higher-risk patients in a setting of improved opera-
tive and perioperative care may not yield similar results.
CONCLUSIONS
Despite its inherent limitations, this study provides com-
pelling evidence that BITA compared with SITA grafting
provides enhanced long-term survival with no increase in
OM or morbidity for comparable patients with both normal
and reduced left ventricular function. BITA grafting should
be the operation of choice in patients with a life expectancy
beyond 1 to 2 decades.The Journal of Thoracic and CaThe authors thank Debra D. Guest, EdD, for technical assis-
tance in the preparation of this report.References
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Dr Anthony Furnary (Portland, Ore). Dr Galbut, you and
your coauthors have presented a nonrandomized series of BITA
and SITA groups and divided them into terciles of EF. Propensity
matching was done using 14 preoperative variables, and both raw
and unmatched were presented. There was a 14-year follow-up in
group I, less than 30%, and no differences in operative or survival
were seen. There were survival differences in the group with 30%
to 50% EF and the group with greater than 50% EF. In the re-
duced group with 30% to 50% EF, there was a 22-year follow-
up and a raw mortality difference of 17% at 10 years, which
amounted to approximately a 5-year difference in median sur-
vival in the unmatched population. Now when the groups were
propensity matched, those numbers decreased from 17% at 10
years to 4% at 10 years and the median survival decreased
from 5 years to approximately 2 years. The number of patients
who are left at the end of the whole thing at 20 years was less
than 5% of the patient population, and there are only 37 matched
patients at 20 years. I do not think we can make any statistically
valid conclusions on those data. In the normal EF group and the
greater than 50% EF group, there was a 28-year follow-up with
a raw mortality difference of approximately 16% at 10 years
and 12% at 20 years, which amounted to a 4.4% difference in me-
dian survival. Now once again when the groups were propensity
matched using those 14 characteristics, the differences were
markedly reduced again from 17% to 7% at 10 years and from
12% to 2% at 20 years, and the median survival was now down
to 7 months when the propensity matching was carried out. So
statistically speaking, as we all know with nonrandomized and
retrospective studies, when there are significant differences in
the raw outcomes that become smaller and smaller with the
more matching and risk adjustment we do, we really have to
look closely at the risk adjustment techniques and the statistical
techniques to find out if there is anything we missed that might
account for the remaining differences. Because retrospective
studies, as you know, cannot prove causality, we have to take
a critical look at that. There are at least 2 variables that may
not have been accounted for in this incredible study that may
have had an impact on long-term survival. The 2 things that I
looked at in your data (and I appreciate the article in advance)
are year of operation and operating surgeon or operating center.
Year of operation is important because the salutary effects of
newer adjunctive treatments that came to the fore over the 22852 The Journal of Thoracic and Cardiovascular Surgyears of this study between 1972 and 1994 on long-term survival
are significant, such as myocardial protection techniques, the ad-
vent of statins, and the use of beta-blockers, angiotensin-convert-
ing enzyme inhibitors, and implantable cardioverter defibrillators
to prolong survival (especially for those with lower EF). The year
of operation might be an important piece to put in there to miti-
gate some of those factors. I have 5 questions for you.
What was the distribution of patients with SITA versus BITA
over time? Were there more patients with a SITA operated on ear-
lier? Obviously you were a pioneer in this area, but what about the
other centers and surgeons? Is it possible that if there were more
SITA cases operated on earlier, some of these adjunctive therapies
might account for some of the differences in those SITA versus
BITA?
Dr Galbut. The article is extensive in the statistical analyses,
which in all valuations are significant, although I agree that the
percentage may not be large as we go up to 20+ years. Many short-
comings exist in this study, all of which were mentioned and al-
luded to in the article, and we are now looking at age. Age is
perhaps the most important factor, where if you follow patients
longer you see the value of the BITA grafting, and I believe it is
greater in the moderately impaired EF group, 30% to 50%, than
in patients with normal EF.
In regard to your specific question, at the time of this study, pri-
marily from 1985 to 1996, all of the surgeons were together in 1
institution, and then as our community changed and our institution
proliferated into several, I can only comment anecdotally about my
colleagues. Currently the majority have gotten away from BITA
grafting. I don’t know if that answers your question, but during
the time from 1985 to 1994, almost every year 45% to 50% of pa-
tients had BITA grafts. It is unusual in that the broad application is
not seen in other institutions, and it was inspired by our group hav-
ing a major interest in this area.
Dr Furnary.Would it be pretty simple to add the year of oper-
ation to your propensity matching?
Dr Galbut. Yes.
Dr Furnary. I think you should try that, and it might mitigate
some of those points that we brought up. Was there any difference
in operating surgeons; so this was 1 center, same surgeons?
Dr Galbut. I do not believe there were major differences. The
overall operative mortalities were low.
Dr Furnary.Were radial arteries used in your practice, and how
did you account for those?
Dr Galbut. Yes. We used them for a short while. Our belief is
that the radial artery is not as advantageous as the in situ right in-
ternal thoracic artery (RITA) graft, and therefore it is easier to con-
struct as an anastomosis, but our group has not used them in any
large number.
Dr Furnary. In severely ischemic patients in whom we oper-
ate with coronary bypass, that often improves EF, and it seems to
me that study categorization by preoperative EF assumes that the
EF does not change, that is, operate on someone with a 30% EF
and postoperatively it goes to 50% or 55%, and they are now
in the category for survival of the 50% EF. Would it be possible
to use postoperative EF rather than preoperative EF for
categorization?
Dr Galbut. It would be great. That is another limitation of the
study, and we accept that.ery c April 2012
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gle Cox regression instead of one for each group, a single Cox re-
gression that would take into account EF as a variable?
Dr Galbut. Late EF?
Dr Furnary. No, even preoperative because we cannot get EF
postoperatively or we do not have it in every patient.
Dr Galbut. Specific EF or the group?
Dr Furnary. One single Cox regression for the entire cohort of
patients, groups I, II, and III, using EF as one of the variables.
Dr Galbut.One of our limitations, because the study goes back
to a group that ended in 1994, is that the data registry has EF only in
3 categories, so it would be hard to say patient 2000 had an EF of
34%, and that is discussed in the article as a major limitation.
Dr Furnary. Final question. Deep sternal wound infection. I
noticed that your group uses skeletonized thoracic arteries, which
is great, and there was no effect on deep sternal wound infection
between bilateral and single. But there are other covariates or co-
factors that also impart an increased risk, and usually bilateral tho-
racic artery grafting with some of those cofactors, such as diabetes,
COPD, immune deficiency, obesity, is what has been shown in the
literature to significantly increase deep sternal wound infection.
Did you do any subanalyses?The Journal of Thoracic and CaDrGalbut. In a prior article presented this year to the American
Heart Association, we looked at diabetes, and within this group
there was no increased incidence.
Dr Furnary. Great. Richard?
DrRichard Shemin (Los Angeles, Calif). An incredible study. I
cannot wait to see the whole article. I assume that the left internal
thoracic artery (LITA) primarily always went to the left anterior
descending (LAD). What was the strategy for the RITA?
Dr Galbut. Excellent question. The LITAwent to the LAD. For
a short while, wewere using the RITA to the LAD and the LITA se-
quentially to circumflex branches. I never believed in that because in
90% of patients, the LITA is the most important and dominant ves-
sel. LITA to the LAD will confer longevity, so that should not be
risked. We wrote an article a couple years ago with Dr Kurlansky,
who looked at where we placed the RITA, and what was noted is
that it did not matter where the RITA was placed, whether it was
to a proximal circumflex like a ramus or an important diagonal or
the right coronary. I started taking the skeletonized RITA through
the transverse sinus to gain length and anastomose it to a circumflex
obtuse marginal branch one in the 1980s. To answer your question,
my strategy, and I think the majority in the article, was to use the
LITA to the LAD and the RITA to whichever artery was the best fit.rdiovascular Surgery c Volume 143, Number 4 853
APPENDIX E1. Preoperative variables and risk factors in unmatched ejection fraction groups
Variable
Group I
unmatched patients
EF<0.30
Group II
unmatched patients
EF 0.30–0.50
Group III
unmatched patients
EF>0.50
SITA BITA P value SITA BITA P value SITA BITA P value
No. of patients 146 (100.0) 87 (100.0) 656 (100.0) 600 (100.0) 1538 (100.0) 1510 (100.0)
Gender .242 <.001 .001
Male 119 (81.5) 76 (87.4) 525 (80.0) 535 (89.2) 1,094 (71.1) 1,258 (83.3)
Female 27 (18.5) 11 (12.6) 131 (20.0) 65 (10.8) 444 (28.9) 252 (16.7)
Age at operation
Mean  SD 66.9  9.7 63.2  9.4 .004 68.0  8.8 62.4  10.5 <.001 67.3  9.6 63.1  9.8 <.001
Coronary risk factors
Family history of CAD 72 (49.3) 45 (51.7) .722 321 (48.9) 313 (52.2) .252 790 (51.4) 834 (55.2) .032
Hypertension 60 (41.1) 16 (18.4) <.001 236 (36.0) 204 (34.0) .464 568 (36.9) 586 (38.8) .285
Dyslipidemia 20 (13.7) 8 (9.2) .307 99 (15.1) 99 (16.5) .494 227 (14.8) 236 (15.6) .504
Smoking history 95 (65.1) 62 (71.3) .329 384 (58.5) 394 (65.7) .009 867 (56.4) 917 (60.7) .015
Diabetes mellitus 50 (34.2) 23 (26.4) .214 198 (30.2) 140 (23.3) .006 391 (25.4) 294 (19.5) <.001
Preoperative risk factors
Renal dysfunction 6 (4.1) 5 (5.7) .569 39 (5.9) 21 (3.5) .042 60 (3.9) 38 (2.5) .030
Cerebrovascular disease 10 (6.8) 7 (8.0) .734 43 (6.6) 17 (2.8) .002 88 (5.7) 51 (3.4) .002
Peripheral artery disease 13 (8.9) 8 (9.2) .940 48 (7.3) 27 (4.5) .035 75 (4.9) 58 (3.8) .162
Prior myocardial infarction 117 (80.1) 69 (79.3) .879 493 (75.2) 435 (72.5) .285 742 (48.2) 660 (43.7) .012
History of CHF 52 (35.6) 24 (27.6) .206 150 (22.9) 71 (11.8) <.001 138 (9.0) 93 (6.2) .003
Unstable angina 104 (71.2) 59 (67.8) .582 456 (69.5) 374 (62.3) .007 1,058 (68.8) 866 (57.4) <.001
Coronary angiography
3-vessel disease 131 (89.7) 80 (92.0) .574 564 (86.0) 526 (87.7) .377 1,236 (80.4) 1,229 (81.4) .471
EF, Ejection fraction; SITA, single internal thoracic artery; BITA, bilateral internal thoracic artery; CHF, chronic heart failure; CAD, coronary artery disease; SD, standard
deviation.
APPENDIX E2. Comparison of operative data for propensity-matched ejection fraction groups
Variable
Group I
matched patients
EF<0.30
Group II
matched patients
EF 0.30–0.50
Group III
matched patients
EF>0.50
SITA BITA P value SITA BITA P value SITA BITA P value
No. of patients 87 (100.0) 87 (100.0) 448 (100.0) 448 (100.0) 1137 (100.0) 1137 (100.0)
Total grafts
Distal grafts .031 .972 .999
Mean  SD 3.2  0.9 3.5  0.9 3.2  0.9 3.3  0.9 3.2  0.9 3.3  0.9
Range 2-6 2-5 2-6 2-6 2-6 2–6
Cardiopulmonary bypass time
Perfusion time (min) .663 .305 .325
Mean  SD 130.4  41.3 133.6  54.1 126.0  49.6 122.7  47.9 115.1  43.9 113.3  43.2
Range 55-245 55-391 15-386 25-444 29-504 31–422
Aortic crossclamp time (min) .009 <.001 <.001
Mean  SD 71.1  25.2 80.9  23.4 70.5  24.9 76.4  24.4 65.5  22.3 71.7  23.0
Range 13-185 37-158 10-176 12-200 10-237 16–200
EF, Ejection fraction; SITA, single internal thoracic artery; BITA, bilateral internal thoracic artery; SD, standard deviation.
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APPENDIX E3. Definition of Terms
Preoperative variables: Hypertension was defined as blood
pressure (140 systolic or 90 diastolic) on 2 occasions or
currently on antihypertensive medication.Hypercholestere-
mia was defined as a cholesterol of>200 mg/dL on admis-
sion to the hospital. Renal insufficiency was defined as
a documented history of renal failure with a creatinine of
 2.0 mg/dL or on dialysis.
Surgical urgency: Elective surgery was defined as an op-
eration, which could be deferred without increased risk of
compromised cardiac outcome. Urgent surgery was defined
as being required within 48 hours in an effort to prevent fur-
ther clinical deterioration. Emergency surgery was defined
as those instances when the patient had intractable angina
or heart failure that did not respond to aggressive clinical
measures or had impending infarction, or when decompen-
sation occurred in the cardiac catheterization laboratory and
measures such as defibrillation, extended cardiac massage,
balloon counterpulsation, or inotropic support were
required.
Postoperative variables: Respiratory insufficiency was
defined as patients requiring ventilatory support for> 48
hours or tracheostomy (or both). CVAwas defined as a neu-
rologic deficit that remained unresolved and presented for>
24 hours. Perioperative MI was defined as a new onset of Q
waves with or without elevation of myocardial enzyme or
a substantial elevation of myocardial enzymes alone. Renal
insufficiency was defined as a documented history of renal
failure with a creatinine of  2.0 mg/dL or on dialysis.
Low cardiac output syndrome was defined as clinical evi-
dence of hypotension, oliguria, and peripheral vascular con-
striction with normal or supranormal left ventricular filling
pressure or a measured cardiac index of< 2 L/min1/m2,
necessitating the administration of catecholamines, use of
intra-aortic balloon pump, or both. Deep sternal infection
was defined as instability of the sternum with positive
wound cultures necessitating an additional surgical proce-
dure, such as incision and drainage, debridement, or sec-
ondary closure. Hospital mortality was defined as death
occurring during the operation or the hospitalization in
which the procedure was performed or death occurring after
discharge from the hospital but within 30 days of the surgi-
cal procedure, unless the cause was clearly unrelated to the
operation.
APPENDIX E4. Covariates Used to Generate
Propensity Scores
Preoperative variables
1. Age at operation
2. Cerebrovascular disease
3. Diabetes mellitus
4. Diseased vessels
5. Dyslipidemia
6. Family history of coronary artery disease
7. Gender
8. Congestive heart failure
9. Hypertension
10. Peripheral artery disease
11. Prior myocardial infarction
12. Renal dysfunction
13. Smoking history
14. Unstable angina
APPENDIX E5. Covariates Used to Predict In-Hospital
Mortality
Preoperative variables
1. Age at operation
2. Cerebrovascular disease
3. Diabetes mellitus
4. Family history of coronary artery disease
5. Gender
6. Congestive heart failure
7. Intra-aortic balloon pump inserted preoperatively
8. Left main disease
9. Peripheral artery disease
10. Prior myocardial infarction
11. Renal dysfunction
12. Smoking history
13. Surgical urgency
14. Unstable angina
Intraoperative variables
15. Aortic crossclamp time
16. Distal grafts
17. Group (SITA vs BITA)
APPENDIX E6. Covariates Used to Predict Late
Mortality
Preoperative
1. Age at operation
2. Cerebrovascular disease
3. Congestive heart failure
4. Diabetes
5. Dyslipidemia
6. Family history of coronary artery disease
7. Gender
8. Hypertension
9. Intra-aortic balloon pump inserted preoperatively
10. Left main disease
11. Peripheral arterial disease
12. Prior myocardial infarction
13. Renal disease
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14. Smoking history
15. Surgical history
16. Surgical urgency
17. 3-vessel disease
18. Unstable angina
Intraoperative
19. Aortic crossclamp time
20. Distal grafts
21. Perfusion time
Postoperative
22. Cardiac arrest
23. Cerebrovascular accident
24. Deep sternal wound infection
25. Gastrointestinal disorder
26. Low cardiac output
27. Postoperative myocardial infarction
28. Pulmonary insufficiency
29. Renal dysfunction
30. Reoperation for bleeding
APPENDIXE7. Multivariate analysis of demographic and preoperative clinical variables associatedwith hospital mortality in unmatched ejection
fraction groups
Group/predictor b estimate SE Chi-square P value* OR 95% CI
Group I, EF<0.30
Age at operation 0.061 0.0268 6.14 .013 1.1 1.0-1.1
Intra-aortic balloon pump inserted preoperatively 1.304 0.4812 8.06 .005 3.7 1.4-9.5
Group II, EF 0.30–0.50
Age at operation 0.048 0.0167 9.44 .002 1.0 1.0-1.1
Congestive heart failure 0.755 0.2969 6.09 .014 2.1 1.2-3.8
Intra-aortic balloon pump inserted preoperatively 1.609 0.2868 31.00 <.001 5.0 2.8-8.8
Aortic crossclamp time (min) 0.013 0.0050 6.24 .012 1.0 1.0-1.0
Group III, EF>0.50
Age at operation 0.049 0.0139 13.68 <.001 1.1 1.0-1.1
Intra-aortic balloon pump inserted preoperatively 1.716 0.2482 42.15 <.001 5.6 3.4-9.0
Aortic crossclamp time (min) 0.018 0.0040 18.92 <.001 1.0 1.0-1.0
OR, Odds ratio; SE, standard error; CI, confidence interval; EF, ejection fraction. *Only significant variables (P<.050) are listed.
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APPENDIX E8. A, Unmatched group I SITA and BITA recipients (EF<0.30). B, Unmatched group II SITA and BITA recipients (EF 0.30–0.50). C, Un-
matched group III SITA and BITA recipients (EF>0.50).
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